Masood Khan joins KCAS team
Becomes senior director of ligand binding assay services
For nearly 20 years, Dr Khan has led wide-ranging research on strategic planning for LBA programmes, as well as the development of GLP-compliant and non-GLP assays for the conduct of ligand binding studies. He has chaired and organised many conferences and lectures at annual forums and meetings of the American Association of Pharmaceutical Scientists’ (AAPS) and has helped establish the LBAB-Focus Group, a specialist division of AAPS.
Dr Khan has worked in executive capacities for several contract research organisations (CROs) and pharmaceutical companies including MDS Life Sciences, Covance, NeuroBiotech, Medlmmune and most recently the National Institute of Health.
Dr Khan received his PhD in biochemistry from Aligarh University, India, and has conducted post-doctoral studies at the National Institute of Environmental Health Sciences in North Carolina and McGill University, Royal Victoria Hospital in Canada.
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Packaging
Cloud labelling and serialisation: the new frontline of traceability in drug delivery
As drug delivery evolves to accommodate a new wave of data-driven innovation, the need for traceability and compliance throughout the supply chain is paramount. Innovative cloud-based solutions enable pharmaceutical companies to navigate these demands with confidence
Manufacturing
Sharp boosts autoinjector and pen assembly line capability with $20m investment in Pennsylvania facility
The money will boost its autoinjector and pen assembly, labelling and packaging lines across various therapeutic areas at its facility in Macungie, meeting the rising demand for injectables